Brief: FDA Authorizes Starton Therapeutics To Proceed With Star-LLD Lenalidomide Phase 1b Clinical Trial
12/06/2023 22:23
June 12 (Reuters) - Healthwell Acquisition Corp I
HWEL.O :
* STARTON THERAPEUTICS RECEIVES AUTHORIZATION FROM THE FDA
TO
PROCEED WITH STAR-LLD LENALIDOMIDE PHASE 1B CLINICAL TRIAL IN
MULTIPLE MYELOMA
* STARTON THERAPEUTICS - FDA AGREES TO THE PLANNED PHASE 1B
STUDY
IN SECOND-LINE TRANSPLANT-INELIGIBLE PATIENTS IN MULTIPLE
MYELOMA
Further company coverage: HWEL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Healthwell Acquisition I
See all newsBrief: Healthwell Acquisition Corp. I Announces Cancellation Of Special Stockholder Meeting And Its Intention To Liquidate
Brief: Healthwell Acquisition Announces Termination Of Business Combination With Starton Therapeutics
Brief: Healthwell Acquisition Corp. I Announces Postponement Of The Special Meeting Of Stockholders To Approve The Proposed Business Combination With Starton Therapeutics And Related Transactions
Brief: FDA Authorizes Starton Therapeutics To Proceed With Star-LLD Lenalidomide Phase 1b Clinical Trial
Advisory: Incorrect alerts related to Straton Therapeutics withdrawn